Oncology Drug Pricing After ASCO Value Framework and DrugAbacus

Posted by Ed Schoonveld on Tue, Jul 21, 2015

The U.S. medical community has been increasingly vocal over the high cost of oncology drugs and its impact on the ability to treat patients. Oncologists coined the term “financial toxicity” to indicate the need to consider patient cost as a component in treatment decision making.


>
Read More

Prescription Market Stakeholders to Drug Makers: Show Us the Value

Posted by Ed Schoonveld on Thu, Jun 18, 2015

The U.S. market for prescription drugs has evolved significantly over the last few years. High and increasing costs of healthcare, together with changes related to the Patient Protection and Affordable Care Act (ACA), have been at the forefront of discussions. Health insurance coverage for previously uninsured, institution of Accountable Care Organizations (ACOs) and various other healthcare quality and efficiency initiatives have also been prevalent topics.


>
Read More

“Pricing’s Point Man” in Pharmaceutical Executive

Posted by Ed Schoonveld on Thu, May 21, 2015

For the May 2015 issue of Pharmaceutical Executive, I had a chance to sit down with the magazine’s editor-in-chief, William Looney, who interviewed me on the status of market access as a discipline in pharmaceutical companies and the challenges companies are facing in light of the changing environment.


>
Read More

Finding and Funding the Cure for Alzheimer’s Disease

Posted by Ed Schoonveld on Mon, Apr 27, 2015

Alzheimer’s disease (AD) is projected to become a major drain on global health-care systems, with the cost of care for the United States alone amounting to more than $214 billion in 2014 and estimated to grow to $1.2 trillion annually by 2050.1 With limited treatment options, the disease is putting a large and growing humanistic toll on patients and their families. Research efforts have so far been disappointing, as a large number of developmental agents have failed to demonstrate efficacy in reducing symptoms or, preferably, alter progression of the disease. The recent news of positive early stage trial results for Biogen’s aducanumab has renewed hope for effective solutions for this devastating disease. However, many challenges remain in finding and funding new treatments.


>
Read More

Can Payers and Industry Agree on Drug Values? Seven Steps for Consensus

Posted by Ed Schoonveld on Thu, Apr 02, 2015

In my blog post, Can Payers and the Drug Industry Agree on Real Value?, I discussed the difficulty of meeting payer evidence requirements at time of launch, given limitations on the ability to meet value-related requirements within the FDA- or EMA-mandated trial requirements, as well as cost and time requirements to deliver some longer-term outcomes.


>
Read More